Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 172c; offers guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $245.85 -1.25%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
OFLX, NMRD, VAXX, More
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
OFLX, NMRD, VAXX, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $6.34, $1.72 better than the analyst estimate of $4.62. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $981.08 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2026 revenue of $4.25-4.5 billion, versus the consensus of $4.453 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- Actelis Networks (ASNS) Tops Q2 EPS by 63c
- Faraday Future Intelligent Electric Inc. (FFAI) Tops Q2 EPS by $20.87, Misses on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
